诺雷德与米非司酮预防子宫内膜异位症术后复发的临床观察

目的:探讨诺雷德与米非司酮用于盆腔子宫内膜异位症术后辅助治疗的疗效及安全性。方法:回顾分析了83例盆腔子宫内膜异位症术后应用诺雷德、米非司酮及未用药组的复发率和不良反应发生率。结果:诺雷德组、米非司酮组复发率分别为13.33%,17.07%,低于未用药组33.33%(P<0.05)。米非司酮组不良反应发生率14.63%,显著低于诺雷德组66.67%(P<0.05)。结论:诺雷德、米非司酮用于盆腔子宫内膜异位症的术后辅助治疗有效,米非司酮不良反应少。

Clinical observation on the effects of mifepristone and GnRH-a for postoperative pelvic endometriosis

Objective To study the effects and safety of mifepristone and GnRH-a for postoperative pelvic endometriosis.Methods Eighty-three pelvic endometriosis cases were analyzed retrospectively,in which 41 were given mifepristone(mifepristone group),15 were given gestrinone(gestrinone group) and other 27 cases didn't take any drugs(control group).Recurrence rate and adverse effect rate were compared among these groups.Results The recurrence rates of mifepristone group and GnRH-a group were 13.3% and 17.1%,respectively,significantly lower than that of control group(P<0.05,P<0.05).The adverse effect rate of mifepristone group was 14.6%,which was significantly lower than that of gestrinone group(66.7%)(P<0.05).Conclusion Mifepristone and gestrinone are effective for postoperative pelvis endometriosis.Mifepristone has less adverse effects than that of gestrinone.